Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
Several clinical pharmacokinetic studies of ebrotidine (N-[(E)-[[2-[[[2-[(diaminomethylene)amino]-4-thiazolyl] methyl]thio]ethyl]amino]methylene]-4-bromo-benzenesulfonamide, CAS 100981-43-9, FI-3542) administered by oral route in single and multiple doses to healthy volunteers have been performed. Dosage levels were 150, 300, 400, 500, 600 and 800 mg. Plasma concentrations of unchanged ebrotidine and its major metabolite, ebrotidine sulfoxide, excreted in the urine were determined. The main pharmacokinetic parameters were calculated from the experimental data. Absorption was relatively rapid (Imax = 2 h) and unrelated to dose. Drug behavior was considered as reasonably linear: Cmax = 364-1168 ng/ml and AUC0-12 h = 1427-5997 ng.h/ml (doses from 150 mg to 800 mg). The mean values of terminal elimination half-life (t1/2 beta) ranged from 13.9 to 20.3 h (doses of 400, 600 and 800 mg). After multiple dosing there was no drug accumulation, and no significant changes in the mean values of the main pharmacokinetic parameters were observed. The steady state was reached from the second day of administration, 10-24% of the ebrotidine administered dose was excreted in urine mainly as its major metabolite, ebrotidine sulfoxide, as well as unchanged drug and other minor metabolites. These percentages were constant and independent of the dose administered.